Loading polyaniline (PANI) nanoparticles to mesoporous hydroxyapatite (HAp) spheres for near infrared (NIR) induced doxorubicin (DOX) drug delivery and colon cancer treatment

In response to the pressing need for more efficient and targeted cancer therapies, this study presents the development of biodegradable hydroxyapatite/polyaniline (HAp/PANI) nanocomposite drug carriers for near-infrared (NIR)-induced drug delivery. The synthesis involved loading polyaniline onto mesoporous hydroxyapatite spheres, resulting in high drug loading capacity and tunable NIR responsiveness. The HAp/PANI spheres exhibited superior photothermal properties compared to pristine HAp under NIR irradiation, along with excellent biocompatibility. Importantly, the drug release behavior could be precisely controlled by adjusting NIR power and irradiation time, leading to enhanced anticancer efficacy against HCT-116 colorectal cancer cells. These findings highlight the potential of HAp/PANI mesoporous spheres as promising drug carriers for NIR-responsive cancer therapy.

Facile synthesis of porous MoS2nanofibers for efficient drug delivery and cancer treatment

Porous MoS₂nanofibers were synthesized by electroplating and post-annealing and applied in a responsive drug delivery system. The one-dimensional (1D) MoS₂nanofibers displayed a high specific surface area, controllable morphology, and uniform size, serving as a promising drug carrier for chemotherapy. After surface modification with polyethylene glycol (PEG) through PEGylation, the MoS₂/PEG composite displayed excellent physical/chemical stability and biocompatibility. More importantly, MoS₂/PEG loaded with doxorubicin (DOX) exhibited a controllable release responsive to pH and near-infrared (NIR) irradiation and demonstrated precise DOX dose release. Such remarkable anticancer effects were mainly attributed to outstanding photothermal performance and stability of porous MoS₂nanofibers. This work offered a new opportunity of employing porous MoS₂nanofibers as drug carriers for effective cancer chemotherapy.

Controlling drug release from mesoporous silica through an amorphous, nanoconfined 1-tetradecanol layer

Mesoporous silica materials are promising nano-carriers for drug delivery systems. Even though there are many strategies for controlling the drug release kinetics, these must be adapted through trial and error on a case-by-case basis. Here we explore the possibility of tailoring the release kinetics of hydrophilic, water soluble therapeutic agents from mesoporous silica through addition of a hydrophobic excipient, 1-tetradecanol. In vitro drug release experiments performed at 37 °C, in phosphate buffer solution (pH 7.4) show that the addition of tetradecanol yields slower drug release kinetics, which was correlated with the presence of a liquid fatty alcohol interfacial layer. The layer mass is 11-23 wt.% of the metoprolol-loaded silica sample, and it causes up to 1.6 times decrease of initial release rate with respect to materials without the fatty alcohol. This effect does not depend of carrier pore arrangement, being noticed for both hexagonal MCM-41 and cubic KIT-5 mesoporous silica. The toxicity of tetradecanol-containing materials was evaluated by formazan-based viability assay on Opossum kidney epithelial cell line, and no significant toxicity was observed.